UCB SA (BR:UCB) — Market Cap & Net Worth
Market Cap & Net Worth: UCB SA (UCB)
UCB SA (BR:UCB) has a market capitalization of $44.56 Billion (€38.12 Billion) as of June 4, 2026. Listed on the BR stock exchange, this Belgium-based company holds position #607 globally and #3 in its home market, demonstrating a 3.11% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying UCB SA's stock price €251.90 by its total outstanding shares 190361362 (190.36 Million). Review UCB SA balance sheet liabilities to assess the company's total debt and financial obligations.
UCB SA Market Cap History: 2015 to 2026
UCB SA's market capitalization history from 2015 to 2026. Data shows growth from $16.80 Billion to $56.06 Billion (13.91% CAGR).
Index Memberships
UCB SA is a constituent of 6 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
BEL-20 INDEX
BEL20
|
$370.84 Billion | 12.02% | #3 of 20 |
|
BEL-20 INDEX
BFX
|
$370.84 Billion | 12.02% | #3 of 20 |
|
BEL All Share
BSPT
|
$842.48 Billion | 5.29% | #6 of 108 |
|
STOXX Europe Large 200 EUR Price
LCXP
|
$7.02 Trillion | 0.63% | #46 of 182 |
|
STOXX Europe Large 200 Net Return
LCXR
|
$7.02 Trillion | 0.63% | #46 of 182 |
|
EuroNext 100
N100
|
$3.48 Trillion | 1.28% | #23 of 97 |
Weight: UCB SA's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
UCB SA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how UCB SA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
6.86x
UCB SA's market cap is 6.86 times its annual revenue
Latest Price to Earnings (P/E) Ratio
34.08x
UCB SA's market cap is 34.08 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $12.44 Billion | $4.15 Billion | $520.00 Million | 3.00x | 23.92x |
| 2017 | $13.67 Billion | $4.47 Billion | $753.00 Million | 3.05x | 18.15x |
| 2018 | $14.93 Billion | $4.63 Billion | $800.00 Million | 3.22x | 18.66x |
| 2019 | $15.02 Billion | $4.91 Billion | $792.00 Million | 3.06x | 18.97x |
| 2020 | $18.09 Billion | $5.35 Billion | $732.00 Million | 3.38x | 24.72x |
| 2021 | $21.74 Billion | $5.78 Billion | $1.06 Billion | 3.76x | 20.55x |
| 2022 | $16.07 Billion | $5.52 Billion | $418.00 Million | 2.91x | 38.44x |
| 2023 | $17.43 Billion | $5.25 Billion | $343.00 Million | 3.32x | 50.80x |
| 2024 | $42.77 Billion | $6.15 Billion | $1.06 Billion | 6.95x | 40.16x |
| 2025 | $53.10 Billion | $7.74 Billion | $1.56 Billion | 6.86x | 34.08x |
Competitor Companies of UCB by Market Capitalization
Companies near UCB SA in the global market cap rankings as of June 4, 2026.
Key companies related to UCB SA by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #227 globally with a market cap of $108.72 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #428 globally with a market cap of $63.77 Billion USD.
- Argen-X (BR:ARGX): Ranked #644 globally with a market cap of $41.72 Billion USD ( €35.68 Billion EUR).
- Argen-X (F:1AE): Ranked #645 globally with a market cap of $41.67 Billion USD ( €35.64 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #227 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $108.72 Billion | $428.34 |
| #428 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.77 Billion | $618.95 |
| #644 | Argen-X | BR:ARGX | $41.72 Billion | €695.40 |
| #645 | Argen-X | F:1AE | $41.67 Billion | €678.20 |
UCB SA Historical Marketcap From 2015 to 2026
Between 2015 and today, UCB SA's market cap moved from $16.80 Billion to $ 56.06 Billion, with a yearly change of 13.91%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €56.06 Billion | +5.57% |
| 2025 | €53.10 Billion | +24.14% |
| 2024 | €42.77 Billion | +145.47% |
| 2023 | €17.43 Billion | +8.44% |
| 2022 | €16.07 Billion | -26.09% |
| 2021 | €21.74 Billion | +20.17% |
| 2020 | €18.09 Billion | +20.43% |
| 2019 | €15.02 Billion | +0.65% |
| 2018 | €14.93 Billion | +9.22% |
| 2017 | €13.67 Billion | +9.85% |
| 2016 | €12.44 Billion | -25.94% |
| 2015 | €16.80 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 4th, 2026 the market cap of UCB SA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $44.56 Billion USD |
| MoneyControl | $44.56 Billion USD |
| MarketWatch | $44.56 Billion USD |
| marketcap.company | $44.56 Billion USD |
| Reuters | $44.56 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About UCB SA
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, … Read more